ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 267 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,159,066 | -25.3% | 340,867 | -0.8% | 0.01% | -21.4% |
| Q2 2023 | $12,253,631 | +139542.5% | 343,624 | -0.5% | 0.01% | +27.3% |
| Q1 2023 | $8,775 | -37.5% | 345,485 | -0.2% | 0.01% | -42.1% |
| Q4 2022 | $14,043 | -99.9% | 346,231 | +5.5% | 0.02% | +18.8% |
| Q3 2022 | $10,844,000 | -2.6% | 328,095 | +3.8% | 0.02% | 0.0% |
| Q2 2022 | $11,130,000 | -16.4% | 316,111 | +9.2% | 0.02% | -5.9% |
| Q1 2022 | $13,314,000 | -29.0% | 289,502 | +2.4% | 0.02% | -26.1% |
| Q4 2021 | $18,746,000 | +6.1% | 282,748 | -0.0% | 0.02% | -4.2% |
| Q3 2021 | $17,660,000 | -24.4% | 282,880 | +0.3% | 0.02% | -22.6% |
| Q2 2021 | $23,349,000 | +21.9% | 281,926 | -2.4% | 0.03% | +19.2% |
| Q1 2021 | $19,162,000 | -16.1% | 288,977 | -2.9% | 0.03% | -18.8% |
| Q4 2020 | $22,838,000 | +76.9% | 297,640 | -0.7% | 0.03% | +60.0% |
| Q3 2020 | $12,909,000 | -10.3% | 299,787 | -10.0% | 0.02% | -16.7% |
| Q2 2020 | $14,394,000 | +60.7% | 333,265 | +7.0% | 0.02% | +26.3% |
| Q1 2020 | $8,957,000 | -53.8% | 311,331 | +2.0% | 0.02% | -40.6% |
| Q4 2019 | $19,370,000 | +140.0% | 305,374 | +6.6% | 0.03% | +113.3% |
| Q3 2019 | $8,070,000 | +7.6% | 286,362 | +1.2% | 0.02% | +7.1% |
| Q2 2019 | $7,501,000 | +229.0% | 283,046 | +127.8% | 0.01% | +250.0% |
| Q1 2019 | $2,280,000 | +58.3% | 124,276 | +7.2% | 0.00% | +33.3% |
| Q4 2018 | $1,440,000 | -4.7% | 115,963 | +47.1% | 0.00% | 0.0% |
| Q3 2018 | $1,511,000 | +32.3% | 78,815 | -6.2% | 0.00% | +50.0% |
| Q2 2018 | $1,142,000 | +745.9% | 83,982 | +14.8% | 0.00% | – |
| Q1 2017 | $135,000 | +60.7% | 73,128 | +34.4% | 0.00% | – |
| Q4 2016 | $84,000 | -81.8% | 54,398 | -13.3% | 0.00% | -100.0% |
| Q3 2016 | $461,000 | +24.9% | 62,713 | -9.6% | 0.00% | 0.0% |
| Q2 2016 | $369,000 | +7.3% | 69,391 | -2.9% | 0.00% | 0.0% |
| Q1 2016 | $344,000 | – | 71,445 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |